stockrow
Monday 9 November 2026
Export IFRX’s income statement to Excel — free account
InflaRx N.V.
IFRXInflaRx N.V.’s revenue for fiscal 2025 (year ended December 2025) was $33,200.00, down 81.5% from fiscal 2024.
- Revenue
- −128.9%
- EPS
- +90.9%
- Free cash flow
- +59.8%
Quarter to September 2026, against a year earlier
1.31
0.05
−3.68%
Follow IFRX
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Sep ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | 0 | 0 | 0 | 0 | (30.3%) | 0 | 0 | 0 | (24.6%) | |
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (743.48) | (1,900.78) | (24,666.87) | (26,762.42) | (24,666.9) pt | ||||||
| EBT | (10) | (27) | (35) | (60) | (39) | (54) | (31) | (46) | (50) | (52) | (34) | +20.1% | ||||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (67,612.15) | (27,781.83) | (155,470.48) | 0.00 | (155,470.5) pt | ||||||
| Net income | (10) | (27) | (35) | (60) | (39) | (54) | (31) | (46) | (50) | (52) | (32) | +20.2% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | (351.65) | (2.94) | (1.40) | (2.29) | (1.44) | (1.30) | (0.71) | (0.84) | (0.85) | (0.77) | (0.39) | (49.4%) | ||||||
| Cash flow | (196.63) | (1.46) | (1.12) | (1.86) | (1.54) | (1.13) | (0.80) | (0.74) | (0.89) | (0.59) | (0.14) | (47.5%) | ||||||
| Capex | (2.09) | (0.02) | (0.04) | (0.03) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (50.2%) | ||||||
| Free cash flow | (198.72) | (1.48) | (1.15) | (1.89) | (1.55) | (1.14) | (0.81) | (0.75) | (0.89) | (0.60) | (0.14) | (47.5%) | ||||||
| Book value | (1,011.65) | 14.34 | 7.12 | 4.61 | 3.29 | 2.99 | 2.11 | 2.02 | 1.13 | 0.70 | 1.13 | n/m | ||||||
| Shares, m | 0 | 9 | 25 | 26 | 27 | 42 | 44 | 55 | 59 | 67 | 101 | +137.4% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | — | — | — | 0.00 | 811.22 | 2,220.94 | 6,308.89 | 1,010.7 | ||||||
| P/B | — | — | — | — | — | — | — | 0.81 | 2.19 | 1.45 | 1.16 | 1.5 | ||||||
| EV/Sales | — | — | — | — | — | — | — | 0.00 | 461.86 | 411.26 | 1,845.43 | 291.0 | ||||||
| EV/FCF | — | — | — | — | — | — | — | 0.18 | (1.57) | (0.31) | (2.74) | (0.6) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (6) | (14) | (28) | (48) | (42) | (47) | (36) | (41) | (53) | (40) | (20) | +24.6% | |||||
| Capex | 0 | 0 | (1) | (1) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | +18.1% | ||||||
| Free cash flow | (6) | (14) | (29) | (49) | (42) | (47) | (36) | (41) | (53) | (40) | (21) | +24.5% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 31 | 135 | 178 | 118 | 87 | 91 | 89 | 100 | 62 | 46 | 120 | +4.6% | |||||
| Net debt | (32) | (139) | (185) | (129) | (93) | (99) | (86) | (98) | (63) | (55) | (137) | +6.2% | ||||||
| Shareholders’ equity | (28) | 135 | 179 | 120 | 89 | 125 | 93 | 111 | 66 | 47 | 166 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (10.88) | (31.66) | (21.44) | (36.80) | (32.77) | (43.39) | (24.28) | (38.81) | (46.94) | (71.35) | (25.90) | (60.5) pt | |||||
| ROIC | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (136.29) | (500.66) | (295.14) | (1,042.21) | 0.00 | (87.31) | 0.0 pt | ||||||
| ROE | (17.21) | (51.42) | (22.44) | (39.92) | (37.16) | (50.57) | (28.55) | (45.25) | (56.17) | (91.00) | (30.98) | (73.8) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 17 | 21 | 38 | 45 | 49 | 59 | 48 | 66 | 74 | 65 | — | +16.1% | |||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Dec 2025 · fundamentals updated 5 Nov 2026
InflaRx N.V. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| SLGL Sol-Gel Technologies Ltd. | $206.3M | — (loss-making) | — (loss-making) | −96.58% (below 0%: shrinking) | n/m | −8.76% (below 0%: shrinking) | 100.00% | (704.23%) | Compare |
| RNAC Cartesian Therapeutics, Inc. | $205.1M | — (loss-making) | — (loss-making) | −92.91% (below 0%: shrinking) | −7.84% (below 0%: shrinking) | −6.15% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| DRUG Bright Minds Biosciences Inc. | $204.2M | — (loss-making) | — | — | n/m | −124.63% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| PLX Protalix BioTherapeutics, Inc. | $202.2M | 10.5× | 10.6× | +27.07% (above 0%: growing) | +2,280.95% (above 0%: growing) | −94.09% (below 0%: shrinking) | 60.99% | 23.48% | Compare |
| PALI Palisade Bio, Inc. | $202.2M | 1.8× | — (loss-making) | +19,900.00% (above 0%: growing) | n/m | −318.44% (below 0%: shrinking) | 100.00% | (2,339.60%) | Compare |
| ARTV Artiva Biotherapeutics, Inc. | $201.9M | — (loss-making) | — (loss-making) | — | n/m | +13.60% (above 0%: growing) | 100.00% | 0.00% | Compare |
| IKT Inhibikase Therapeutics, Inc. | $200.9M | — (loss-making) | — (loss-making) | −100.00% (below 0%: shrinking) | n/m | −123.23% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ELDN Eledon Pharmaceuticals, Inc. | $199.9M | — (loss-making) | — | — | n/m | −28.02% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| IFRX InflaRx N.V. | $199.7M | — (loss-making) | — (loss-making) | −128.93% (below 0%: shrinking) | n/m | +59.76% (above 0%: growing) | 14,029.95% | 0.00% | |
| Median of peers | $202.2M | — | — | −92.91% | — | −61.05% | 80.50% | 0.00% |